*** Disclaimer: This Database is still undergoing update on daily basis to prevent errors, discrepancies, and missing records. Please Contact FDIC@nafdac.gov.ng for enquires ***

Product Details

JYNA DARUNAVIR 400MG

Darunavir
400 mg
Tablet

ROA

Oral

Applicant Name

Jyna Pharma Ltd

NRN

A4-100045

Status

Active


ATC Code

J05AE1  

Product Category

Drugs

Marketing Category

Prescription-only Medicine (POM)  

Packsize

 

Product Description

JYNA DARUNAVIR 400MG A4-100045 DARUNAVIR TABLETS 400 MG "DARUNAVIR = (R, AS, AR)-HEXAHYDROFURO [-B]FURAN-- YL(SR)--[[(- AMINO PHENYL)SULFONYL](-METHYLPROPYLAMINO]--BENZYL-- HYDROXYPROPYL] CARBAMATE). = CHNOS MICROCRYSTALLINE CELLULOSE USP,NF = FILLER/BINDER COLLOIDAL SILICON DIOXIDE USP,NF = GLIDANT/ DISINTEGRANT =MICROCRYSTALLINE CELLULOSE USP,NF = MICROCRYSTALLINE CELLULOSE USP,NF CROSCARMELLOSE SODIUM USP,NF = CROSCARMELLOSE SODIUM USP,NF POLYVINYL ALCOHOL-PARTIALLY HYDROLYZED = FILM COATING MATERIAL TITANIUM DIOXIDE = FILM " ANTI-INFECTIVES ORAL (3R, 3AS, 6AR)- [2,3-B]FURAN-3- YL(1S,2R)-3-[[(4- ](2-MINO]-1-BENZYL-2- C27H37N3O7S TABLET, FILM COATED PRESCRIPTION ONLY MEDICINE (POM) DARUNAVIR TABLETS, CO-ADMINISTERED WITH LOW DOSE RITONAVIR ARE INDICATED IN COMBINATION WITH OTHER ANTIRETROVIRAL MEDICINAL PRODUCTS FOR THE TREATMENT OF PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV-1) INFECTION. JYNA PHARMA LTD NIGERIA LAURUS LABS INDIA 2021-05-07 2026-05-06

Manufacturer Name

Laurus Labs

Manufacturer Country

INDIA  

Approval Date

2021-05-07  

Expiry Date

2026-05-06